

16 May, 2018

For immediate release

International Panel Puts Intellectual Property Incentives Framework Under Microscope as Prices of New Medicines Rise in Europe

Special meeting held by Health Action International assembles EU lawmakers, institutions and civil society to discuss Framework's deleterious impact on access to medicines

BRUSSELS—European Union (EU) lawmakers and a panel of international experts called today for greater EU Member State use of the [flexibilities](#) offered within the Trade-related Aspects of Intellectual Property (TRIPS) Agreement to improve access to medicines.

Health Action International (HAI) Policy Advisor, Jaume Vidal, said:

“Today’s discussion reflects the urgent need to debate the role of patents and other IP-incentives on access to medicines. Given the growing public outrage and challenges posed by high medicine prices, the EU must use all tools at its disposal to make new medicines more affordable and available.”

The meeting—organised by HAI and hosted by MEPs Nessa Childers (S&D) and José Inácio Faria (EPP)—brought together policy-makers and other civil society groups to discuss the impact of intellectual property rights on access to medicines, along with the tools that Member States have at their disposal to combat rising medicine prices in the EU and beyond.

Speaking during the meeting, Nessa Childers MEP, said:

“An important message we need to heed is that we must reverse course on Trade-Related Aspects of Intellectual Property Rights, to fully implement and promote the flexibilities and safeguards allowed under trade law”.

José Inácio Faria MEP added:

“A balance needs to be achieved between incentives for medicines innovation, affordability of care and sustainability of Health systems.”

TRIPS flexibilities can be considered ‘policy spaces’ for countries to mitigate the impact (i.e., the high price of patented medicines) of certain TRIPS measures. Alongside other IP management tools, TRIPS flexibilities are an effective tool to promote and achieve public health goals, such as access to life-saving medicines.

For interview requests and further information, please contact:

Alex Lawrence | Communications Advisor | Health Action International

T: +31 20 412 4523 | M: +31 61832 1612 | alex@haiweb.org



Health Action International is a non-profit organisation that conducts research and advocacy to advance policies that enable access to medicines and rational medicine use for all people around the world. We pursue advocacy from the patient level up to the highest levels of government through our 'official relations' status with the World Health Organization and respected relationship with the European Medicines Agency. To safeguard our objectivity and integrity, we are resolutely independent of the pharmaceutical industry and protect ourselves from all other conflicts of interest.

- END -



This document received funding under an operating grant from the European Union's Health Programme (2014-2020). Its content represents the views of Health Action International only and is the organisation's sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency, or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.